...
search icon
bntx-img

BioNTech SE, Common Stock

BNTX

NSQ

$98.76

+$0.51

(0.52%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$23.20B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$76.53 L
$131.49 H
$98.76

About BioNTech SE, Common Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBNTXSectorS&P500
1-Week Return6.06%0.44%0.24%
1-Month Return-2.08%-7.69%-7.32%
3-Month Return-11.77%-3.35%-12.05%
6-Month Return-13.72%-11.09%-9.73%
1-Year Return14.31%-2.13%5.05%
3-Year Return-38.11%-1.18%20.03%
5-Year Return142%34.44%83.31%
10-Year Return593.54%84.87%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue482.32M18.98B17.31B3.82B2.75B[{"date":"2020-12-31","value":2.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.22,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true},{"date":"2024-12-31","value":14.5,"profit":true}]
Cost of Revenue704.36M3.86B4.53B599.80M541.30M[{"date":"2020-12-31","value":15.54,"profit":true},{"date":"2021-12-31","value":85.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.23,"profit":true},{"date":"2024-12-31","value":11.94,"profit":true}]
Gross Profit(222.04M)15.12B12.78B3.22B2.21B[{"date":"2020-12-31","value":-1.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.54,"profit":true},{"date":"2023-12-31","value":21.3,"profit":true},{"date":"2024-12-31","value":14.62,"profit":true}]
Gross Margin(46.03%)79.66%73.82%84.29%80.32%[{"date":"2020-12-31","value":-54.61,"profit":false},{"date":"2021-12-31","value":94.5,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.29,"profit":true}]
Operating Expenses(139.62M)200.10M135.90M2.53B3.52B[{"date":"2020-12-31","value":-3.96,"profit":false},{"date":"2021-12-31","value":5.68,"profit":true},{"date":"2022-12-31","value":3.86,"profit":true},{"date":"2023-12-31","value":71.76,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(82.42M)15.28B12.64B690.40M(1.31B)[{"date":"2020-12-31","value":-0.54,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.72,"profit":true},{"date":"2023-12-31","value":4.52,"profit":true},{"date":"2024-12-31","value":-8.6,"profit":false}]
Total Non-Operating Income/Expense(66.89M)(263.20M)622.80M845.40M1.06B[{"date":"2020-12-31","value":-6.3,"profit":false},{"date":"2021-12-31","value":-24.79,"profit":false},{"date":"2022-12-31","value":58.67,"profit":true},{"date":"2023-12-31","value":79.63,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(145.80M)15.05B12.95B1.19B(677.70M)[{"date":"2020-12-31","value":-0.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.09,"profit":true},{"date":"2023-12-31","value":7.88,"profit":true},{"date":"2024-12-31","value":-4.5,"profit":false}]
Income Taxes(161.00M)4.75B3.52B255.80M(12.40M)[{"date":"2020-12-31","value":-3.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.04,"profit":true},{"date":"2023-12-31","value":5.38,"profit":true},{"date":"2024-12-31","value":-0.26,"profit":false}]
Income After Taxes15.20M10.29B9.43B930.30M(665.30M)[{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false}]
Income From Continuous Operations15.20M10.29B9.43B930.30M(665.30M)[{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income15.20M10.29B9.43B930.30M(665.30M)[{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false}]
EPS (Diluted)0.0739.6936.933.83(2.81)[{"date":"2020-12-31","value":0.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":9.65,"profit":true},{"date":"2024-12-31","value":-7.08,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BNTX
Cash Ratio 6.65
Current Ratio 7.45
Quick Ratio 7.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BNTX
ROA (LTM) -3.53%
ROE (LTM) -3.36%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BNTX
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BNTX
Trailing PE NM
Forward PE 7.04
P/S (TTM) 8.63
P/B 1.08
Price/FCF NM
EV/R 1.63
EV/Ebitda 110.81
PEG 0.04

FAQs

What is BioNTech SE share price today?

BioNTech SE (BNTX) share price today is $98.76

Can Indians buy BioNTech SE shares?

Yes, Indians can buy shares of BioNTech SE (BNTX) on Vested. To buy BioNTech SE from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BioNTech SE be purchased?

Yes, you can purchase fractional shares of BioNTech SE (BNTX) via the Vested app. You can start investing in BioNTech SE (BNTX) with a minimum investment of $1.

How to invest in BioNTech SE shares from India?

You can invest in shares of BioNTech SE (BNTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in BNTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BioNTech SE shares
What is BioNTech SE 52-week high and low stock price?

The 52-week high price of BioNTech SE (BNTX) is $131.49. The 52-week low price of BioNTech SE (BNTX) is $76.53.

What is BioNTech SE price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BioNTech SE (BNTX) is 1.08

What is the Market Cap of BioNTech SE?

The market capitalization of BioNTech SE (BNTX) is $23.20B

What is BioNTech SE’s stock symbol?

The stock symbol (or ticker) of BioNTech SE is BNTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top